• Sartorius confirmed fiscal 2026 constant-currency sales growth guidance of approximately 5%-9%, with an underlying EBITDA margin slightly above 30%.
• Sales growth is expected in the range’s lower half, including customer compensation linked to a €40 million tariff refund application.
• Lab Products & Services growth should reach approximately 6%, the range’s upper end; its margin outlook rose to slightly above 21%.
• The capital expenditure forecast fell to approximately 12% of sales from 12.5%; net debt-to-underlying EBITDA remains projected slightly above 3 times.
• The outlook follows nine-month operational sales growth of 8.1%, with underlying EBITDA reaching €827.8 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sartorius AG published the original content used to generate this news brief on October 22, 2026, and is solely responsible for the information contained therein.